Editorial
doi: 10.18683/germs.2017.1115.
eCollection 2017 Sep.
2-Drug regimens in HIV treatment: pharmacological considerations
- PMID: 28932710
- PMCID: PMC5601093
- DOI: 10.18683/germs.2017.1115
Item in Clipboard
Editorial
2-Drug regimens in HIV treatment: pharmacological considerations
Germs.
.
No abstract available
Conflict of interest statement
Conflicts of interest: DB has received honoraria for speaking or advising and research grants (to the institution) from AbbVie, Gilead, Janssen, Merck and ViiV.
Similar articles
-
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433. doi: 10.7326/0003-4819-137-5_part_2-200209031-00001. Ann Intern Med. 2002. PMID: 12617573
-
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55. MMWR Recomm Rep. 2002. PMID: 12027060
-
Pharmacological considerations in antiretroviral therapy.Antivir Ther. 1998;3 Suppl 4:9-12. Antivir Ther. 1998. PMID: 10723503 Review.
-
The effects of alternative treatments for HIV disease on recommended pharmacological regimens.Int J Antimicrob Agents. 2000 Feb;13(4):281-5. doi: 10.1016/s0924-8579(99)00132-6. Int J Antimicrob Agents. 2000. PMID: 10755242
-
Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV.Curr Pharm Des. 2019;25(5):556-576. doi: 10.2174/1381612825666190320162507. Curr Pharm Des. 2019. PMID: 30894103 Review.
Cited by
-
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.Clin Infect Dis. 2020 Nov 5;71(8):1920-1929. doi: 10.1093/cid/ciz1243. Clin Infect Dis. 2020. PMID: 31905383 Free PMC article. Clinical Trial.
-
Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.Viruses. 2022 Nov 25;14(12):2626. doi: 10.3390/v14122626. Viruses. 2022. PMID: 36560630 Free PMC article.
-
Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.Antimicrob Agents Chemother. 2024 May 2;68(5):e0150423. doi: 10.1128/aac.01504-23. Epub 2024 Apr 8. Antimicrob Agents Chemother. 2024. PMID: 38587380 Free PMC article. Clinical Trial.
-
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.Clin Infect Dis. 2022 Sep 29;75(6):975-986. doi: 10.1093/cid/ciac036. Clin Infect Dis. 2022. PMID: 35079789 Free PMC article. Clinical Trial.
-
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318. doi: 10.1097/QAI.0000000000002275. J Acquir Immune Defic Syndr. 2020. PMID: 31834000 Free PMC article. Clinical Trial.
References
-
- Lundgren JD, Gatell JM, Rockstroh JK, Furrer H. EACS Guidelines, version 8.2. London: European AIDS Clinical Society (EACS); 2017.
-
- Cahn P. Candidates for inclusion in a universal antiretroviral regimen: dolutegravir. Curr Opin HIV AIDS. 2017;12:318–23. - PubMed
-
- Margolis DA, Gonzalez-Garcia J, Stellbrink H-J, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017 pii: S0140-6736(17)31917-7. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources